Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 48 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 45 46 47 48 presentations: 1 to 25 of 1185
Educational Session 1: Cancer Genomics
Somatic alterations in human cancer genomes
Matthew L. Meyerson
Dana-Farber Cancer Inst., Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 19, 2013 3:00 PM-4:30 PM
Educational Session 1: Cancer Genomics
Challenges and opportunities for genomic medicine
P. Andrew Futreal
UT MD Anderson Cancer Ctr., Houston, TX, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 19, 2013 3:00 PM-4:30 PM
Educational Session 1: Cancer Genomics
Advances and future of finding cancer associated genes
Gad Getz
Broad Inst. of MIT and Harvard, Cambridge, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 19, 2013 3:00 PM-4:30 PM
Educational Session 2: PI3K and MEK Pathway Inhibitors
BRAF and RAS signaling in melanoma: From basic biology to clinical exploitation
Richard M. Marais
Cancer Research UK Manchester Institute, Manchester, United Kingdom
from 2013 Molecular Targets and Cancer Therapeutics conference on October 19, 2013 4:45 PM-6:15 PM
Educational Session 2: PI3K and MEK Pathway Inhibitors
Title to be announced
Neal Rosen
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 19, 2013 4:45 PM-6:15 PM
Educational Session 2: PI3K and MEK Pathway Inhibitors
Matrix-dependent adaptive resistance to targeted therapy
Joan S. Brugge
Harvard Medical School, Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 19, 2013 4:45 PM-6:15 PM
Opening Remarks and Keynote Lectures
Welcome and Opening Remarks
Jeffrey A. Engelman
Massachusetts General Hospital, Charlestown, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 8:00 AM-10:05 AM
Opening Remarks and Keynote Lectures
Wnt signaling, Lgr5 stem cells, and cancer
Hans Clevers
Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences & University Medical Centre, Utrecht, Netherlands
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 8:00 AM-10:05 AM
Opening Remarks and Keynote Lectures
Targeting the PD-1 pathway: Resetting the balance between the immune system and cancer
Suzanne L. Topalian
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 8:00 AM-10:05 AM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Using synthetic lethality to find effective combination therapies for cancer
René Bernards
Netherlands Cancer Inst., Amsterdam, Netherlands
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Mechanisms of resistance to RAF/MEK inhibitors
David B. Solit
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Overcoming acquired resistance to first-generation kinase inhibitors in lung cancer
William Pao
Vanderbilt Univ., Nashville, TN, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Mechanisms of acquired resistance to ALK/ROS1 inhibitors
Alice T. Shaw
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 2: Targeting the Metabolic Basis of Cancer
The metabolic phase of the cell cycle
Eyal Gottlieb
Cancer Research UK, Beatson Institute, Glasgow, United Kingdom
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 3:15 PM-5:15 PM
Plenary Session 2: Targeting the Metabolic Basis of Cancer
The genetic basis of kidney cancer: A metabolic disease
W. Marston Linehan
National Cancer Inst., Bethesda, MD, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 3:15 PM-5:15 PM
Plenary Session 2: Targeting the Metabolic Basis of Cancer
Ras-induced macropinocytosis: Metabolic adaptation to signaling in the absence of adequate nutrients
Craig B. Thompson
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 3:15 PM-5:15 PM
Plenary Session 2: Targeting the Metabolic Basis of Cancer
IDH mutations and tumorigenicity
Katharine E. Yen
Agios Pharmaceuticals, Cambridge, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 3:15 PM-5:15 PM
Proffered Paper Session 1
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael Burns
Vanderbilt University School of Medicine, Nashville, TN, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 5:30 PM-6:30 PM
Proffered Paper Session 1
LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6-- Reactivating Rb in cancer
Sunkyu Kim
Novartis Institutes for Biomedical Research, Cambridge, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 5:30 PM-6:30 PM
Proffered Paper Session 1
Selective sensitization of mutant K-Ras cancer cells to DNA damage based therapies by targeting wild type H- and N-Ras
Elda Grabocka
NYU Langone Medical Center, New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 5:30 PM-6:30 PM
Proffered Paper Session 1
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
Katherine Hutchinson
Vanderbilt University, Nashville, TN, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 5:30 PM-6:30 PM
Plenary Session 3: Epigenetic Regulators as Therapeutic Targets
Working together to identify new epigenetic targets for cancer
Chas Bountra
University of Oxford, Oxford, United Kingdom
from 2013 Molecular Targets and Cancer Therapeutics conference on October 21, 2013 8:00 AM-10:00 AM
Plenary Session 3: Epigenetic Regulators as Therapeutic Targets
Targeting enhancers in cancers
James E. Bradner
Dana-Farber Cancer Inst., Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 21, 2013 8:00 AM-10:00 AM
Plenary Session 3: Epigenetic Regulators as Therapeutic Targets
Designing p300/CBP histone acetyltransferase inhibitors for cancer
Philip A. Cole
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 21, 2013 8:00 AM-10:00 AM
Plenary Session 3: Epigenetic Regulators as Therapeutic Targets
Protein methyltransferase inhibitors as personalized cancer therapeutics
Robert A. Copeland
Epizyme, Inc., Cambridge, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 21, 2013 8:00 AM-10:00 AM
<< first | < prev page: of 48 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 45 46 47 48 presentations: 1 to 25 of 1185